Global drugmakers have no plans to leave Russia, say local sources

1 March 2022

Russian drugmaker and global pharma companies will significantly reduce the production of anti-COVID-19 vaccines, however the same plans are not considered in case of other drugs, according to recent statements by representatives of producers and some media, reports The Pharma Letter’s local correspondent.

According to producers, the situation with the coronavirus pandemic in Russia is gradually improving, so there will be no need for the production of anti-COVID-19 vaccines in the same volumes as in the past.

Most producers are unable to predict a further development of situation in Russia although the ongoing military conflict with Ukraine and a sharp drop of Russian economy has not yet resulted in the decline of any major demand for drugs in the local market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK